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Background: Guidelines recommend that patients with atrial fibrillation (AF) are involved in 
oral anticoagulant (OAC) treatment decisions. Understanding which OAC attributes AF 
patients value most could help optimize treatment.  
Methods:  A cross-sectional online survey was conducted in patients with nonvalvular AF 
taking an OAC for stroke prevention in the United States, Canada, Germany, France, and 
Japan. Patients were asked about their stroke knowledge, perception of the seriousness of AF 
and concern about stroke, and to rank seven OAC attributes in order of importance. A 
conjoint analysis was performed to determine the inherent value of four attributes.  
Results:  937 patients (mean [SD] 54.3 [16.6] years; 37.1% female) participated. Of these, 
19.5%, 27.9%, and 29.8% had good, moderate, and low stroke knowledge, respectively; 
22.8% had no stroke knowledge. Overall, 39.4% of patients (47.5% with good stroke 
knowledge) perceived AF as very/extremely serious.  
The OAC attribute ranked as most important was stroke prevention followed by major 
bleeding risk, other side effects, dosing frequency, antidote availability, dietary restrictions 
and use with/without food. In the conjoint analysis, stroke risk reduction was the most valued 
property, followed by reduction in major bleeding risk, less frequent administration, and 
administration with/without food. Preferences did not differ with level of stroke knowledge, 
perception of seriousness of AF, concern of stroke, or medication burden.  
Conclusions:  Most AF patients consider efficacy and safety to be the most important OAC 
attributes, whereas dosing frequency was deemed as less important. 
KEYWORDS 
atrial fibrillation, conjoint analysis, oral anticoagulants, stroke knowledge, patient preference 
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1 INTRODUCTION 
Current treatment guidelines for stroke prevention in patients with atrial fibrillation (AF) 
recommend patient involvement in decisions, 1-3 to improve adherence to medication and 
clinical outcomes. 1,4 However, many AF patients have a poor understanding of the condition 
and limited knowledge regarding stroke and oral anticoagulants (OACs). 4-9 Many studies of 
stroke knowledge have been conducted in the general population 10-15 and in individuals with 
a variety of stroke risk factors 16 rather than AF patients specifically,  and to our knowledge, 
the relationship between stroke knowledge and OAC preferences in the AF population has 
not been assessed.  
A better understanding of the patient viewpoint, and the extent to which patients value 
individual OAC attributes, could help physicians to decide on the most appropriate treatment 
in collaboration with the patient, as recommended by the guidelines.  
The objective of our study was to assess the relationship between patients’ stroke knowledge 
and their preferences for specific OAC attributes, using 2 methods: (i) a ranking exercise and 
(ii) a choice-based conjoint analysis. The study also assessed whether patient preferences 
differed with respect to medication burden, perception of seriousness of AF, concern about 
stroke, and whether patients had a recent or established AF diagnosis, with or without a 
recent stroke.  
 
2 METHODS 
A cross-sectional, multinational (the United States, Canada, Germany, France, and Japan) 
survey was conducted in adults (≥18 years) with nonvalvular AF receiving an OAC for stroke 
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prevention. Patients were recruited through consumer panels, or by telephone or face-to-face 
contact resulting from referrals from physicians, nurses or other patients, or from patient 
associations or social media. Patients were stratified into three groups: newly diagnosed AF 
(within the previous 6 months; [12 months in Japan]) without recent stroke; established AF 
(diagnosed between 7–24 months previously;[1–3 years previously in Japan]) without recent 
stroke; and AF (diagnosed at any time) with a recent stroke (within the past 6 months). 
Patients completed a 30-minute online questionnaire on stroke knowledge, perception of AF 
and stroke, current medication burden, and views on OACs. Three open-ended questions on 
etiology, stroke symptoms, and risk factors were used to categorize patients as having a good, 
moderate, or low level of stroke knowledge, or no stroke knowledge, using a predefined 
scoring system (Supplemental Table 1).  
Patients were asked how many different medications they took daily; the daily frequency of 
their oral medication; how serious they considered AF to be; how frequently they were 
concerned by stroke risk; how much they wanted to be involved in OAC treatment decisions; 
and which sources they used, if any, to obtain information regarding their current OAC. 
Patients were asked how familiar they were with standardized information regarding AF, 
stroke, and the potential benefits and risks of OACs (Supplemental Table 2). 
2.1 Ranking Exercise  
Before being exposed to the standardized information, patients ranked by order of importance 
the following OAC attributes (which were presented in a random order): stroke prevention, 
major bleeding risk, other side effects, dosing frequency, antidote availability, dietary 
restrictions, and whether medication needed to be taken with food.  
2.2 Choice-based Conjoint Analysis 
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After the standardized information had been presented, patients were asked which of three 
hypothetical products they would be most willing to take to prevent a stroke. Each product 
profile was characterized by specific levels for four attributes: stroke risk reduction, major 
bleeding risk, frequency of administration, and administration with/without food (Figure 1; 
Supplemental Table 3). For each hypothetical product, stroke risk was either the same as, or 
21% or 36% lower than standard therapy; major bleeding risk was either the same as, or 20% 
or 31% lower than standard therapy. These figures were based on the results of ARISTOTLE 
and RE-LY, where the rate of stroke was 21% and 36% lower with apixaban and dabigatran 
(150 mg), respectively vs warfarin and the major bleeding rate was 31% and 20% lower with 
apixaban and dabigatran (110 mg), respectively vs warfarin. 17-19 Each hypothetical product 
was dosed once or twice daily and  could be taken with or without food. 
Patients were asked to perform the hypothetical product selection a total of ten times. The 
utility value of each characteristic was determined using logistic regressions based on a 
Bayesian analysis. Points were awarded to each attribute level every time it appeared in the 
patient’s chosen hypothetical product profile (+1 if chosen, –1 if not chosen, 0 if not 
presented) and each attribute level was given a utility value.  
Results were assessed for the overall study population and according to AF subgroups, stroke 
knowledge, medication burden, perceived seriousness of AF, and concern about stroke risk. 
Three quality control assessments, increasing in stringency, were included to ensure that 
patients gave considered answers rather than random responses (Supplementary Table 4).  
Descriptive statistics are presented as mean and standard deviation (SD) for normally 
distributed continuous variables; categorical data are presented as a number and percentage. 
Differences between groups were compared using independent sample t-tests (means) and 
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chi-squared tests (categorical data). P values comparing three or more subgroups relate to 
data of one group vs other subgroups combined. 
Informed consent was obtained from all participants. The survey was conducted in 
accordance with the Principles of the Declaration of Helsinki. 
 
3 RESULTS 
Between April and November 2015, 937 AF patients completed the survey from the United 
States (n = 322), Canada (n = 145), Germany (n = 160), France (n = 171), and Japan (n 
=139), with an overall mean (SD) age of 54.3 (16.6) years; 37.1% were female (Table 1). Of 
the 937 patients, 19.5%, 27.9%, and 29.8% demonstrated good, moderate, and low levels of 
stroke knowledge, respectively; 22.8% had no stroke knowledge. Stroke knowledge was 
independent of educational level, and significantly lower in those with AF and a recent stroke 
vs those with no recent stroke (32.5% of patients with a recent stroke had no stroke 
knowledge vs 20.3% of those without a recent stroke). 
The most commonly known stroke symptoms were numbness/weakness/paralysis of the face, 
arm(s), leg(s) (known by 54.9% of patients), followed by confusion or trouble speaking or 
understanding speech (41.8%), dizziness (22.2%), trouble seeing/double vision (15.4%), and 
severe headache with no known cause (14.8%). The most frequently mentioned stroke risk 
factors were high blood pressure/hypertension (37.1%), smoking (26.8%), high 
cholesterol/hypercholesterolemia (19.7%), poor diet and/or lack of physical activity (17.4%), 
and AF (17.4%) (Supplemental Figure 1).  
Familiarity with standardized information was stated to be good in 39% of patients overall, in 
37% of patients with recently diagnosed AF without recent stroke, and in 53% of AF patients 
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with a recent stroke (Supplemental Table 5). Significantly more patients with the lowest 
levels of education (no school-leaving certificate) stated poor levels of familiarity with 
standardized information (37% vs 11–14% in other educational groups). 
Overall, 39.4% of patients (47.5% with good stroke knowledge) perceived AF as 
extremely/very serious. Patients with good or moderate stroke knowledge were more often 
concerned about a stroke than those with no or low knowledge, who were more likely to 
never be concerned about a stroke (Table 1). Better stroke knowledge was associated with a 
preference for joint OAC treatment decision-making (Table 1) and with the use of more 
information sources about current OACs and higher utilization of health care professionals’ 
advice (Supplemental Table 6).  
Patients took a median of three different daily medications (interquartile range 2–6); 21.9% 
of patients took capsules/tablets once daily, 39.6% twice daily, and 38.5% ≥3 times daily. 
 
3.1 Ranking Exercise  
The attribute most often ranked as the most important was stroke prevention (47.4% of 
patients), followed by major bleeding risk (14.7%), other side effects (10.0%), dosing 
frequency (8.2%), antidote availability (7.8), dietary restrictions (7.0%), and administration 
with/without food (4.8%) (Figure 2). The proportions of patients who rated stroke prevention 
as the most important attribute increased as stroke knowledge improved (Figure 2).  
 
3.2 Conjoint Analysis 
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All 937 patients completed a choice-based conjoint analysis; however, answers from 261 
patients did not meet the quality assessments and were excluded, leaving 676 patients (232 in 
the United States, 104 in Canada, 94 in Japan, 123 in France, and 123 in Germany) 
(Supplemental Figure 2). Baseline characteristics are presented in Table 1.  
Overall, patients valued stroke risk reduction as the most important OAC attribute, followed 
by major bleeding risk, frequency of administration, and administration with/without food, 
with utility values of 194.3, 115.9, 32.0, and 29.8, respectively. A 21% reduction in stroke 
risk vs standard therapy brings 77.5 points of utility, whereas a 20% reduction in major 
bleeding risk vs standard therapy results in 83.6 points of utility (Figure 3).  
Stroke prevention was the most important attribute independent of stroke knowledge and was 
valued more highly in patients with better levels of stroke knowledge vs. those with lower 
levels of/no stroke knowledge (Figure 4). The relative level of importance placed on the four 
attributes was consistent across patient groups, regardless of their predefined AF subgroup, 
perceived seriousness of AF, concern about stroke and the frequency that they took oral 
medication (Supplemental Figures 3–6). 
 
4. DISCUSSION 
To our knowledge, this is the largest published study to assess OAC preferences among AF 
patients and is highly relevant to contemporary clinical practice, since patient values are 
increasingly featured in AF management guidelines. 1-3,20,21 OAC attributes relating to 
efficacy and safety were considered the most important in the ranking exercise and conjoint 
analysis, regardless of the AF subgroup, level of stroke knowledge, perception of seriousness 
of AF, concern about stroke, and the frequency of administration.  
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Unlike some previous surveys, 10,14 our study assessed stroke knowledge using open-ended 
questions, which may more accurately reflect a patient’s level of understanding; asking 
patients to select from a list of potential answers may bias results. Patients with a recent 
stroke had significantly lower levels of stroke knowledge than those with no recent stroke, 
even though recent-stroke patients claimed to be highly familiar with the standardized 
information. Those with a recent stroke may have moderate disability or residual cognitive 
impairment, 22-24 which could limit their ability to enter free text or recall answers unaided in 
response to open-ended questions. Patients with recent stroke experience may also find it 
more challenging to confront risk factors associated with the condition, and devote less time 
to open-ended questions.  
Better stroke knowledge was associated with using more information sources regarding 
current OACs, increased use of advice from health care professionals, and a preference for 
joint OAC treatment decision-making. Poor stroke knowledge was common and independent 
of educational level. Only 17.4% of patients named AF as a stroke risk factor, even though all 
respondents had AF. These findings highlight the need for improved healthcare professional-
patient dialogue. 
Pre-existing stroke knowledge did not affect the order in which OAC attributes were ranked 
in the ranking exercise or valued in the conjoint exercise, which were consistent. Information 
from a ranking exercise may be limited, as patients are likely to desire all of the benefits at no 
cost. Assessing patient-perceived values through a conjoint exercise forces patients into 
making a trade-off between positive and negative attributes, more accurately reflecting real 
life where one treatment is selected over others based on its individual profile. 25 
Standardized information regarding AF, stroke and OACs was presented before the conjoint 
analysis, so that stroke knowledge was more consistent across the study population.  
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Our findings are consistent with those from other studies, in which efficacy and safety have 
been rated highly by patients. 6,26-28 Recent systematic reviews focusing on OAC preferences 
in AF patients showed that most patients valued stroke prevention over other attributes. 25,29 
In a study by LaHaye et al, newly diagnosed AF patients were willing to suffer 4.4 major 
bleeds to prevent one stroke, demonstrating the importance placed on efficacy. However, 
12% of patients in the study were unwilling to take antithrombotic therapy even if it was 
100% effective. 28 Of note, our study only included patients taking OAC with an AF 
diagnosis dating back as far as 3 years; those unwilling to take antithrombotic treatment were 
excluded.  
Although AF patients considered stroke risk reduction to be the most important OAC 
attribute in our study, an improvement of 21% over standard therapy appeared to be less 
compelling than a 20% reduction in major bleeding risk.  
Our study is unusual in that we explored the potential impact of stroke knowledge and 
previous stroke on patient preferences regarding OAC attributes. The value placed on each 
attribute was consistent across all subgroups evaluated, including stroke knowledge and 
stroke history; interestingly, frequency of administration was of minor importance, regardless 
of the number of times per day that patients took oral medication. 
The attributes evaluated in the conjoint analysis were chosen because each had a manageable 
number of permutations and could be used to differentiate the currently available NOACs. 
Dabigatran and apixaban are administered twice daily; edoxaban and rivaroxaban are dosed 
once daily and, unlike the other NOACs, rivaroxaban must be taken with food. Dabigatran is 
the only available NOAC for which a specific reversal agent (idarucizumab) is available. 
However, as the survey was conducted largely before its introduction, reversal agent 
availability was not included as an attribute.  
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Previous conjoint analyses or discrete choice experiments focusing on OACs generally 
included modest patient numbers and were not always limited to patients eligible for OAC. 
27,30 In addition some have excluded efficacy and/or safety attributes, and consequently 
findings may. imply that patients place greater importance on convenience factors such as 
dosing frequency. 31,32 The results of our analysis suggest that stroke prevention and major 
bleeding risk are by far the most important factors that concern patients when selecting an 
OAC. 
 
Study Limitations 
This study has certain limitations. Online methodology may have introduced bias toward 
younger patients, males, and those with a higher educational level, however, preferences for 
OAC attributes were independent of age, sex and educational level (data not shown). In 
addition, the survey reflects the views of AF patients taking OACs, whereas in clinical 
practice a considerable proportion of patients are not treated with OACs despite a clear 
indication. 33,34  
In conclusion, the findings of our study suggest that efficacy and safety are considered to be 
the most important OAC attributes by the majority of AF patients. Dosing frequency was 
found to be of minor importance to most AF patients, irrespective of stroke knowledge, 
medication burden, perception of seriousness of AF, or concern about stroke. Understanding 
patients’ needs and preferences with regards to OAC treatment will improve clinical 
outcomes, and as such we believe that our findings should be considered when discussing and 
selecting OACs with AF patients.  
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TABLE 1 Patient characteristics, perceptions and preferences 
  
Stroke knowledge 
Conjoint analysis 
patients 
 Overall Good Moderate Low None  
N (%) 937 (100) 183 (19.5) 261 (27.9) 279 (29.8) 214 (22.8) 676 (100) 
Age, mean (SD) y  54.3 (16.6) 60.7 (12.4)a 57.2 (15.0)a 53.9 (17.0) 45.7 (17.4)a 57.6 (15.5) 
≥65 y, n (%) 309 (33.0) 78 (42.6)a 104 (39.8)a 86 (30.8) 41 (19.2)a 268 (39.6) 
Female, n (%) 348 (37.1) 77 (42.1) 104 (39.8) 96 (34.4) 71 (33.2) 256 (37.9) 
CHA2DS2-VASc score, mean 
(SD) 
2.6 (1.7) 2.8 (1.8) 2.7 (1.7) 2.6 (1.7) 2.5 (1.5) 2.6 (1.7) 
Educational level, %b       
No school-leaving 
certificate 
2.9 2.7 2.3 3.9 2.3 3.1 
High school diploma 27.2 25.7 25.4 30.5 26.6 26.2 
Community college 28.1 27.3 30.0 26.5 28.5 27.7 
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University/technical  41.8 44.3 42.3 39.1 42.5 43.0 
college       
AF status, n (%)       
Newly diagnosed AF, no 
recent stroke 
342 (36.5) 80 (43.7) 91 (34.9)a 99 (35.5) 72 (33.6) 265 (39.2) 
Established AF, no recent 
stroke 
401 (42.8) 84 (45.9) 117 (44.8) 121 (43.4) 79 (36.9)c 308 (45.6) 
AF with recent stroke 194 (20.7) 19 (10.4)a 53 (20.3) 59 (21.1) 63 (29.4) 103 (15.2) 
Perception of seriousness of 
AF, n (%) 
      
Extremely serious/very 
serious 
369 (39.4) 87 (47.5)c 109 (41.8) 109 (39.1) 64 (29.9)a 268 (39.6) 
Somewhat serious 390 (41.6) 76 (41.5) 110 (42.1) 113 (40.5) 91 (42.5) 282 (41.7) 
Not at all/not serious 178 (19.0) 20 (10.9)a 42 (16.1) 57 (20.4) 59 (27.6)a 126 (18.6) 
Concern about stroke, %       
Often/always 43.4 44.8 46.0 40.5 43.0 38.9 
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Occasionally 45.4 50.3 46.0 45.2 40.7 61.1d 
Never/I don’t know 11.2 4.9 8.0 14.3 16.4  
Patient preference for being 
involved in OAC treatment 
choice, % 
      
Doctor choice 44.7 26.8a 37.5a 50.5c 61.2a  
Patient─doctor choice 35.6 51.9a 42.5a 32.3 17.8a  
Patient choice 19.6 21.3 19.9 17.2 21.0  
 
Abbreviations: AF, atrial fibrillation, OAC, oral anticoagulant, SD, standard deviation. 
aFor stroke knowledge, P < 0.001 versus other groups pooled;  bData from 936 patients;  cFor stroke knowledge, P < 0.05 versus other groups pooled;  dNever/occasionally. 
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